首页> 外文OA文献 >The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development
【2h】

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

机译:药代动力学和药效学数据在早期药物开发中药物安全性评估中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The pharmaceutical industry continues to look for ways to reduce drug candidate attrition throughout the drug discovery and development process. A significant cause of attrition is due to safety issues arising either as a result of animal toxicity testing or in the clinical programme itself. A factor in the assessment of safety during early drug development is the pharmacokinetic profile of the compound. This allows safety data to be considered in the light of systemic drug exposure and therefore permits a quantitative assessment. This is particularly applicable when assessing the risk of a new chemical entity (NCE) in relation to safety parameters such as QT interval prolongation, where free plasma concentrations have been shown to be predictive of this property in relation to potency in preclinical testing. Prior to actual human exposure it is therefore important to be able to predict reliably the pharmacokinetic behaviour of an NCE in order to place such safety findings into a quantitative risk context. The emerging science of pharmacogenetics is likely to further our ability to assess the risk of NCEs to populations and individuals due to genetic variance. The drug metabolizing enzyme CYP2D6 has been recognized as providing the potential to result in widely differing systemic drug exposure in the patient population due to polymorphic expression. Further knowledge is likely to add to our understanding of population differences in exposure and response and aid in the identification of risk factors. One potential strategy for improving the effectiveness of the drug discovery process is to obtain clinical pharmacokinetic data more rapidly in order to assess more accurately the potential for both efficacy and safety of an NCE. Whilst procedures and technologies are available that allow this on the microdose scale, it is important that we recognize potential limitations of these approaches in order that they can be applied beneficially.
机译:制药行业一直在寻找减少药物发现和开发过程中候选药物消耗的方法。磨损的主要原因是由于动物毒性试验或临床程序本身引起的安全性问题。在早期药物开发过程中评估安全性的一个因素是该化合物的药代动力学特征。这样可以根据全身性药物暴露情况考虑安全性数据,因此可以进行定量评估。在评估与安全参数(例如QT间隔延长)相关的新化学实体(NCE)的风险时,这尤其适用,在这种情况下,游离血浆浓度已被证明可预测与临床前测试效能相关的该特性。因此,在实际暴露于人类之前,重要的是能够可靠地预测NCE的药代动力学行为,以便将此类安全性发现纳入定量风险范围内。新兴的药物遗传学科学可能会增强我们评估由于基因变异而对人群和个人造成NCE风险的能力。药物代谢酶CYP2D6被认为具有提供潜在的功能,可导致由于多态性表达而导致患者群体中全身性药物暴露差异很大。进一步的了解可能会加深我们对暴露和反应人群差异的理解,并有助于识别风险因素。改善药物发现过程有效性的一种潜在策略是更快地获得临床药代动力学数据,以便更准确地评估NCE的有效性和安全性。尽管有可用的程序和技术可以在微剂量规模上做到这一点,但重要的是,我们必须认识到这些方法的潜在局限性,以便可以对其进行有益的应用。

著录项

  • 作者

    Walker, D K;

  • 作者单位
  • 年度 2004
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号